Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eyenovia (EYEN – Research Report), Alpine Immune Sciences (ALPN – Research Report) and GoodRx Holdings (GDRX – Research Report).
Eyenovia (EYEN)
In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Eyenovia, with a price target of $12.00. The company’s shares closed last Wednesday at $1.06.
According to TipRanks.com, Caufield is a 3-star analyst with an average return of
Currently, the analyst consensus on Eyenovia is a Moderate Buy with an average price target of $11.00.
See today’s best-performing stocks on TipRanks >>
Alpine Immune Sciences (ALPN)
In a report released today, Robert Driscoll from Wedbush reiterated a Hold rating on Alpine Immune Sciences, with a price target of $65.00. The company’s shares closed last Wednesday at $64.97, equals to its 52-week high of $64.97.
According to TipRanks.com, Driscoll is a 4-star analyst with an average return of
Alpine Immune Sciences has an analyst consensus of Hold, with a price target consensus of $61.50, a -5.3% downside from current levels. In a report issued on May 9, RBC Capital also reiterated a Hold rating on the stock with a $65.00 price target.
GoodRx Holdings (GDRX)
Goldman Sachs analyst Eric Sheridan maintained a Hold rating on GoodRx Holdings today. The company’s shares closed last Wednesday at $7.27.
According to TipRanks.com, Sheridan is a 5-star analyst with an average return of
GoodRx Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $9.36, which is a 40.5% upside from current levels. In a report issued on May 9, RBC Capital also maintained a Hold rating on the stock with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EYEN:
- Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
- Eyenovia provides clinical, scientific update on products Mydcombi, Clobetasol
- Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
- Biotech Alert: Searches spiking for these stocks today
- Eyenovia considers strategic alternatives, including possible sale
